Microbiology, Immunology & Infectious Diseases
ProfessorMedicine Microbiology, Immunology & Infectious Diseases (MIID) Member of the Infectious Diseases Research Group Address: 270 Heritage Medical Research Building Phone: (403) 220-5951 Fax: (403) 270-2772 Email: email@example.com
MD, University of Western Ontario
The Adult Cystic Fibrosis Clinic for Calgary and Southern Alberta is the coordinating center for medical trials of the clinical expidemiology of acute pulmonary infection exacerbations in CF patients and the efficacy of newer approaches to the diagnosis and management of their chronic suppurative lower respiratory tract infections. A cohort of adult patients with chronic bronchiectasis are managed in a similar fashion and available for comparative results.
1. Our research involes the assessment of the responses to antibiotic therapies prescribed for Pseudomonas aeruginosa bronchopneumonitis in adult patients with cystic fibrosis. The Adult CF Clinic of Calgary and Southern Alberta is the coordination centre for clinical trials to examine the efficacy of chronic sequential antibiotics to prevent pulmonary function deterioration (CSOCIT -- chronic sequential oral ciproflaxin and inhalation tobramycin).
2. Newer anti-Pseudomonal antibiotics and other therapeutic approaches are assessed as to their efficacies (both bacteriologic and clinical) and whether these will reduce the high incidence of microbial persistence. Is persistence of Pseudomonas aeruginosa the explanation of bacteriologic treatment failure in cystic fibrosis?
3. Antibiotic therapies prescribed to patients with cystic fibrosis may also effectively inhibit Pseudomonas exoenzymes in vivo. Assays of exoenzyme specific mRNA and the in vivo transcript accumulation in sputum may explain why CF patients clinically respond to therapies despite bacteriologic persistence of their infecting strains of P. aeruginosa and the failure of antibiotics to inhibit bacterial replication. This is a collaborative project with Dr. Douglas Storey of the Department of Biological Sciences, University of Calgary.
4. The in vivo assessment of specific lung host defenses important in Pseudomonas infections of patients with cystic fibrosis may help correlate the clinical objective and subjective responses to prescribed anti-Pseudomonal therapies with the quantitative bacteriologic responses and the down regulation of Pseudomonas virulence factors.
5. The clinical epidemiology of cystic fibrosis - ESCF (Epidemiologic Study of Cystic Fibrosis) is a North American multicentre, longitudinal and follow-up investigation for monitoring pulmonary function and pulmonary infection exacerbations. ESCF is designed to examine the patterns of medical practice in cystic fibrosis and to evaluate the monitoring of the health status of CF patients in North America and the appropriate use of specific therapies in their management.